Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RZLT 
Rezolute Inc (RZLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: RZLT (4-star) is a STRONG-BUY. BUY since 41 days. Profits (12.63%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $13.11
1 Year Target Price $13.11
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 102.93% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 387.19M USD | Price to earnings Ratio - | 1Y Target Price 13.11 |
Price to earnings Ratio - | 1Y Target Price 13.11 | ||
Volume (30-day avg) 10 | Beta 1.04 | 52 Weeks Range 2.21 - 6.19 | Updated Date 06/30/2025 |
52 Weeks Range 2.21 - 6.19 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.85% | Return on Equity (TTM) -95.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 302076566 | Price to Sales(TTM) - |
Enterprise Value 302076566 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.01 | Shares Outstanding 86814704 | Shares Floating 76521831 |
Shares Outstanding 86814704 | Shares Floating 76521831 | ||
Percent Insiders 9.65 | Percent Institutions 52.01 |
Analyst Ratings
Rating 4 | Target Price 13.11 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rezolute Inc
Company Overview
History and Background
Rezolute, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases. Founded to address unmet needs, the company is focused on advancing novel therapeutics for conditions like Congenital Hyperinsulinism (CHI).
Core Business Areas
- Drug Development: Focuses on the research and development of new drug candidates for rare metabolic disorders.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Prepares for the commercialization of approved therapies.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Its organizational structure includes research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- RZ358: RZ358 is Rezolute's lead product candidate for the treatment of Congenital Hyperinsulinism (CHI). It is currently in clinical development. Market share is currently 0, as the product is not yet approved. Competitors would include diazoxide and octreotide, as well as surgical interventions.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The rare disease market is growing due to increased awareness and regulatory incentives.
Positioning
Rezolute is positioned as a company focused on developing innovative therapies for rare metabolic diseases. Their competitive advantage lies in their focus and expertise in this niche area.
Total Addressable Market (TAM)
The TAM for Congenital Hyperinsulinism (CHI) is estimated to be significant, given the lack of effective treatment options. Rezolute is positioned to capture a portion of this TAM if RZ358 is approved.
Upturn SWOT Analysis
Strengths
- Focus on rare metabolic diseases
- Novel drug candidate (RZ358)
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on RZ358 for near-term revenue
- High risk of clinical trial failure
Opportunities
- Potential for orphan drug designation and market exclusivity
- Partnerships with larger pharmaceutical companies
- Expansion into other rare metabolic diseases
Threats
- Clinical trial failures
- Competition from other companies developing therapies for CHI
- Regulatory hurdles
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- BMY
- SNY
Competitive Landscape
Rezolute faces competition from established pharmaceutical companies. Its advantage lies in its specialized focus and novel approach.
Growth Trajectory and Initiatives
Historical Growth: Rezolute's historical growth has been driven by the advancement of RZ358 through clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of RZ358. Analyst estimates vary.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and seeking regulatory feedback.
Summary
Rezolute is a clinical-stage company with a focus on rare metabolic diseases. The success hinges on the approval of RZ358. While the focus is a strength, a lack of funds is a major weakness. Clinical trial outcomes and securing partnerships are key for future growth and addressing the weaknesses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rezolute Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-05-01 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Mr. Nevan Charles Elam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | Website https://www.rezolutebio.com |
Full time employees 68 | Website https://www.rezolutebio.com | ||
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.